{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:26:57Z","timestamp":1781756817192,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3030,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.rmed.2004.11.005","type":"journal-article","created":{"date-parts":[[2005,1,19]],"date-time":"2005-01-19T07:31:05Z","timestamp":1106119865000},"page":"S11-S19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S1","title":["Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects"],"prefix":"10.1016","volume":"99","author":[{"given":"Rodger","family":"Kempsford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Handel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariza","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Daley-Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2004.11.005_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0954-6111(05)80060-5","article-title":"Metered-dose inhalers and CFC","volume":"88","author":"Partridge","year":"1994","journal-title":"Respir Med"},{"issue":"Suppl. 1","key":"10.1016\/j.rmed.2004.11.005_bib2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1089\/jam.1995.8.Suppl_1.S-9","article-title":"The continued need for metered-dose inhalers","volume":"8","author":"Boyd","year":"1995","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib3","unstructured":"Command Paper No. 977; Treaty series 1990 (19); Montreal Protocol. Substances that deplete the ozone layer. Montreal, 16th September 1987."},{"key":"10.1016\/j.rmed.2004.11.005_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jam.1995.8.Suppl_1.S-13","article-title":"Montreal protocol and essential use exemptions","volume":"8","author":"D\u2019Souza","year":"1995","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/02786829408959750","article-title":"Approaches and challenges to use freon propellant replacements","volume":"22","author":"Leach","year":"1995","journal-title":"Aerosol Sci Technol"},{"key":"10.1016\/j.rmed.2004.11.005_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jam.1995.8.Suppl_1.S-29","article-title":"Safety of propellants","volume":"8","author":"Alexander","year":"1995","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/096032719501400903","article-title":"An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane)","volume":"14","author":"Alexander","year":"1995","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.rmed.2004.11.005_bib8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.2042-7158.1996.tb05980.x","article-title":"Twenty-eight day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects","volume":"48","author":"Harrison","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.005_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0954-6111(98)90215-3","article-title":"Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol","volume":"92","author":"Thompson","year":"1998","journal-title":"Respir Med"},{"issue":"Suppl 1","key":"10.1016\/j.rmed.2004.11.005_bib10","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1089\/jam.1995.8.Suppl_1.S-35","article-title":"Clinical pharmacology of HFA134a","volume":"8","author":"Ventresca","year":"1995","journal-title":"J Aerosol Med"},{"issue":"Suppl.","key":"10.1016\/j.rmed.2004.11.005_bib11","first-page":"509P","article-title":"GR106642X, a non-chlorinated propellant for use in metered dose inhalers","volume":"37","author":"Denyer","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.005_bib12","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/bmj.310.6995.1639a","article-title":"GR106642X","volume":"310","author":"Taggart","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2004.11.005_bib13","first-page":"161","article-title":"Efficacy of a new non-ozone depleting formulation for salbutamol","volume":"5","author":"Custovic","year":"1995","journal-title":"J Pharm Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1081-1206(10)62385-X","article-title":"Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction","volume":"88","author":"Hawksworth","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmed.2004.11.005_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1081-1206(10)63302-9","article-title":"Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma","volume":"86","author":"Lumry","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl. B","key":"10.1016\/j.rmed.2004.11.005_bib16","first-page":"S29","article-title":"Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group","volume":"94","author":"Tonnel","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/rmed.1999.0678","article-title":"Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma","volume":"94","author":"Farmer","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib18","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.rmed.2004.11.013","article-title":"Development and performance of a new hydrofluroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol","volume":"99","author":"Peyron","year":"2005","journal-title":"Resp Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0169-409X(03)00079-6","article-title":"The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers","volume":"55","author":"Smyth","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.rmed.2004.11.005_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003088-200241010-00003","article-title":"Clinical pharmacokinetics of salmeterol","volume":"41","author":"Cazzola","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmed.2004.11.005_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2004.11.002","article-title":"On behalf of the SMO30006 and SMO30007 international study teams. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma","volume":"99","author":"Chopra","year":"2005","journal-title":"Resp Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib22","unstructured":"Jones AE, Callejas S, Sadra P, Joyce K, Pereira A, Biddlecombe RA, Pleasance S. The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC\u2013MS\u2013MS. In: Proceedings of the 45th ASMS conference on mass spectrometry and allied topics. Palm Springs, June 1\u20135, 1997. p. 560."},{"key":"10.1016\/j.rmed.2004.11.005_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/thx.50.6.679","article-title":"Salmeterol inhaler using a non-chlorinated propellant, HFA134a","volume":"50","author":"Kirby","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2004.11.005_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2125.1992.tb04049.x","article-title":"Dose\u2013response study with high-dose inhaled salmeterol in healthy subjects","volume":"33","author":"Maconochie","year":"1992","journal-title":"Br J Clin Pharmac"},{"key":"10.1016\/j.rmed.2004.11.005_bib25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0090-9556(25)08195-4","article-title":"Disposition of salmeterol xinafoate in laboratory animals and humans","volume":"21","author":"Manchee","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.rmed.2004.11.005_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1081-1206(10)62711-1","article-title":"Cumulative dose response study comparing HFA-134a albuterol sulphate with conventional CFC albuterol in patients with asthma","volume":"81","author":"Ramsdell","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl. B","key":"10.1016\/j.rmed.2004.11.005_bib27","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0954-6111(00)80144-4","article-title":"Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs","volume":"94","author":"Kunka","year":"2000","journal-title":"Repir Med"},{"key":"10.1016\/j.rmed.2004.11.005_bib28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2125.2004.02172.x","article-title":"Comparison of bronchoprotective and bronchodilator effects of single dose formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind placebo-controlled study","volume":"58","author":"Houghton","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.005_bib29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1046\/j.1365-2125.1999.00098.x","article-title":"Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate","volume":"48","author":"Lipworth","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rmed.2004.11.005_bib30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1378\/chest.122.2.510","article-title":"Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone","volume":"122","author":"Leach","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2004.11.005_bib31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1067\/mai.2000.111582","article-title":"Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhlation aerosol), in asthma","volume":"106","author":"Vanden Burgt","year":"2000","journal-title":"J Allergy Clin Immunol"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611104004329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611104004329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:14:05Z","timestamp":1760609645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611104004329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":31,"alternative-id":["S0954611104004329"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2004.11.005","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2004.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}